Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series

Jessica P. Harris; Michael A. Postow; David M. Faleck

doi:10.1093/oncolo/oyac019

Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series

Jessica P. Harris
, Michael A. Postow
, David M. Faleck

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Immune checkpoint inhibitor-related colitis is a common complication of immunotherapy use in patients with cancer. Current guidelines recommend treatment with standard dose infliximab (IFX) for corticosteroid-refractory colitis; however, this case series suggests IFX dose escalation may be a viable treatment option for refractory cases.

Original language	English
Pages (from-to)	E350-E352
Journal	Oncologist
Volume	27
Issue number	4
DOIs	https://doi.org/10.1093/oncolo/oyac019
State	Published - Apr 2022
Externally published	Yes

Access to Document

10.1093/oncolo/oyac019

Cite this

@article{239407dbc83b4d6790f2a356eab0f237,

title = "Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series",

abstract = "Immune checkpoint inhibitor-related colitis is a common complication of immunotherapy use in patients with cancer. Current guidelines recommend treatment with standard dose infliximab (IFX) for corticosteroid-refractory colitis; however, this case series suggests IFX dose escalation may be a viable treatment option for refractory cases.",

author = "Harris, \{Jessica P.\} and Postow, \{Michael A.\} and Faleck, \{David M.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2022. Published by Oxford University Press.",

year = "2022",

month = apr,

doi = "10.1093/oncolo/oyac019",

language = "English",

volume = "27",

pages = "E350--E352",

journal = "Oncologist",

issn = "1083-7159",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis

T2 - A Case Series

AU - Harris, Jessica P.

AU - Postow, Michael A.

AU - Faleck, David M.

N1 - Publisher Copyright: © The Author(s) 2022. Published by Oxford University Press.

PY - 2022/4

Y1 - 2022/4

N2 - Immune checkpoint inhibitor-related colitis is a common complication of immunotherapy use in patients with cancer. Current guidelines recommend treatment with standard dose infliximab (IFX) for corticosteroid-refractory colitis; however, this case series suggests IFX dose escalation may be a viable treatment option for refractory cases.

AB - Immune checkpoint inhibitor-related colitis is a common complication of immunotherapy use in patients with cancer. Current guidelines recommend treatment with standard dose infliximab (IFX) for corticosteroid-refractory colitis; however, this case series suggests IFX dose escalation may be a viable treatment option for refractory cases.

UR - https://www.scopus.com/pages/publications/85128160662

U2 - 10.1093/oncolo/oyac019

DO - 10.1093/oncolo/oyac019

M3 - Article

C2 - 35380715

AN - SCOPUS:85128160662

SN - 1083-7159

VL - 27

SP - E350-E352

JO - Oncologist

JF - Oncologist

IS - 4

ER -

Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series

Abstract

Access to Document

Fingerprint

Cite this